Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibodies to infliximab influence outcomes and drug levels in IBD

January's issue of the American Journal of Gastroenterology reviews the impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with IBD.

News image

Antibodies to infliximab have been associated with loss of clinical response and lower serum infliximab levels in some studies of patients with inflammatory bowel disease (IBD).

This has important implications for patient management and development of novel biologic therapies.

Dr Kavinderjit Nanda from Massachusetts, USA performed a systematic review and meta-analysis of studies that reported clinical outcomes and infliximab levels according to patients’ Antibodies to infliximab status.

MEDLINE, Web of Science, CINAHL, Scopus, and EMBASE were searched for eligible studies.

The researchers reported quality assessment was undertaken using GRADE criteria.

Raw data from studies meeting inclusion criteria was pooled for meta-analysis of effect estimates.

Sensitivity analysis was performed for all outcomes.

The team of doctors reported that a funnel plot was performed to assess for publication bias.

The team identified 13 studies that met the inclusion criteria, and reported results in 1,378 patients with inflammatory bowel disease.

All included studies had a high risk of bias in at least 1 quality domain.

The team of researchers found that the pooled risk ratio of loss of clinical response to infliximab in patients with IBD who had antibodies to infliximab was 3.2, when compared with patients without antibodies to infliximab.

This effect estimate was predominantly based on data from patients with Crohn's disease.

The doctors found that data only from patients with ulcerative colitis exhibited a non-significant relative risk of loss of response of 2.2 in those with antibodies to infliximab.

The standardized mean difference in trough serum infliximab levels between groups was −0.8
American Journal of Gastroenterology

Heterogeneity existed between studies, in both methods of antibodies to infliximab detection, and clinical outcomes reported.

The team observed that 3 studies reported trough serum infliximab levels according to antibodies to infliximab status.

The standardized mean difference in trough serum infliximab levels between groups was −0.8.

A funnel plot suggested the presence of publication bias.

Dr Nanda's team concludes, "The presence of antibodies to infliximab is associated with a significantly higher risk of loss of clinical response to infliximab and lower serum infliximab levels in patients with inflammatory bowel disease."

"Published studies on this topic lack uniform reporting of outcomes."

"High risk of bias was present in all the included studies."

Am J Gastroenterol 2013; 108:40–47
15 January 2013

Go to top of page Email this page Email this page to a colleague

 24 August 2016 
Genetics and therapy response in IBD
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 24 August 2016 
Hep B after infant vaccination program
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery
 01 August 2016 
Relapse after cessation of oral antiviral treatment in Hep B
 01 August 2016 
Antimicrobial resistance of H. pylori
 01 August 2016 
Colorectal cancers in IBD
 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us